遗传性疾病治疗药物研发商Foghorn将在2024年AACR年会期间举办电话会议和网络直播，介绍潜在的首创药物管线-动脉网

Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting

BioSpace 等信源发布 2024-03-26 19:39



可切换为仅中文







Company management will review key pipeline programs, including an update on FHD-286 for AML, new preclinical data for the BRM selective inhibitor FHD-909 and for its selective CBP and EP300 degrader programs

公司管理层将审查关键的管道计划，包括AML的FHD-286更新，BRM选择性抑制剂FHD-909及其选择性CBP和EP300降解剂计划的新临床前数据

Conference call and webcast on April 9th at 5 p.m. ET / 2 p.m. PT

美国东部时间4月9日下午5点/太平洋时间下午2点举行电话会议和网络广播

CAMBRIDGE, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- March 26, 2024 -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced plans to host a conference call and webcast on April 9th at 5 p.m.

马萨诸塞州剑桥市，2024年3月26日（环球通讯社）--2024年3月26日--Foghorn®Therapeutics Inc.（纳斯达克：FHTX），一家临床阶段生物技术公司，开创了一类通过纠正异常基因表达来治疗严重疾病的新型药物，今天宣布计划于4月9日下午5点举行电话会议和网络广播。

ET / 2 p.m. PT. Foghorn management will review key programs in its pipeline, including FHD-286 for acute myelogenous leukemia (AML), and new preclinical data being presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting for potential first-in-class medicines including FHD-909, a BRM (SMARCA2) selective inhibitor, and for the selective CBP and selective EP300 degrader programs..

ET/2 p.m.PT.Foghorn管理层将审查其管道中的关键项目，包括用于急性骨髓性白血病（AML）的FHD-286，以及在2024年美国癌症研究协会（AACR）年会上提交的新临床前数据，用于潜在的一流药物，包括BRM（SMARCA2）选择性抑制剂FHD-909，以及选择性CBP和选择性EP300降解剂项目。。

Conference Call Details

电话会议详细信息

Tuesday, April 9, at 5 p.m. ET / 2 p.m. PT

4月9日星期二，东部时间下午5点/太平洋时间下午2点

Toll Free: 1-877-704-4453

免费电话：1-877-704-4453

International: 1-201-389-0920

国际电话：1-201-389-0920

Conference ID: 13745314

会议编号：13745314

Webcast: Foghorn Events and Presentations

网络广播：雾号事件和演示

About Foghorn Therapeutics

关于Foghorn Therapeutics

Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system.

Foghorn®Therapeutics正在发现和开发一类针对染色质调控系统中遗传决定的依赖性的新型药物。通过其专有的可扩展基因流量控制®平台，Foghorn正在系统地研究，识别和验证染色质调控系统内的潜在药物靶标。

The Company is developing multiple product candidates in oncology. Visit our website at www.foghorntx.com for more information on the Company, and follow us on X (formerly Twitter) and LinkedIn..

该公司正在开发多种肿瘤学候选产品。有关该公司的更多信息，请访问我们的网站www.foghorntx.com，并在X（以前的Twitter）和LinkedIn上关注我们。。

About FHD-286

关于FHD-286

FHD-286 is a highly potent, selective, allosteric, and orally available small-molecule, enzymatic inhibitor of BRG1 (SMARCA4) and BRM (SMARCA2), two highly similar proteins that are the ATPases, or the catalytic engines, of the BAF complex, one of the key regulators within the chromatin regulatory system.

FHD-286是一种高效，选择性，变构和口服可用的小分子，BRG1（SMARCA4）和BRM（SMARCA2）的酶抑制剂，这两种高度相似的蛋白质是BAF复合物的ATP酶或催化引擎，是染色质调节系统中的关键调节器之一。

In preclinical studies, FHD-286 has shown anti-tumor activity across a broad range of malignancies including both hematologic and solid tumors..

在临床前研究中，FHD-286已在包括血液学和实体瘤在内的多种恶性肿瘤中显示出抗肿瘤活性。。

About AML

关于反洗钱

Adult acute myeloid leukemia (AML) is a cancer of the blood and bone marrow and the most common type of acute leukemia in adults. AML is a diverse disease associated with multiple genetic mutations. It is diagnosed in about 20,000 people every year in the United States.

成人急性髓细胞白血病（AML）是一种血液和骨髓癌，是成人最常见的急性白血病类型。AML是一种与多种基因突变相关的多种疾病。在美国，每年约有20000人被诊断出患有此病。

About FHD-909

关于FHD-909

FHD-909 (a.k.a. LY4050784) is a highly potent, allosteric and orally available small molecule that selectively inhibits the ATPase activity of BRM (SMARCA2) over its closely related paralog BRG1 (SMARCA4), two proteins that are the catalytic engines across all forms of the BAF complex, one of the key regulators of the chromatin regulatory system.

FHD-909（又称LY4050784）是一种高效，变构和口服可用的小分子，可选择性抑制BRM（SMARCA2）的ATPase活性，而不是其密切相关的旁系同源物BRG1（SMARCA4），这两种蛋白质是所有形式的BAF复合物的催化引擎，BAF复合物是染色质调节系统的关键调节剂之一。

In preclinical studies, tumors with mutations in BRG1 rely on BRM for BAF function. FHD-909 has shown significant anti-tumor activity across multiple BRG1-mutant lung tumor models..

在临床前研究中，BRG1突变的肿瘤依赖BRM实现BAF功能。FHD-909在多种BRG1突变型肺肿瘤模型中显示出显着的抗肿瘤活性。。

Forward-Looking Statements

前瞻性声明

This press release contains “forward-looking statements.” Forward-looking statements include statements regarding the Company’s clinical trials, product candidates and research efforts, including statements relating to FHD-286, FHD-909 and its selective CBP and EP 300 degrader programs, and other statements identified by words such as “could,” “may,” “might,” “will,” “likely,” “anticipates,” “intends,” “plans,” “seeks,” “believes,” “estimates,” “expects,” “continues,” “projects” and similar references to future periods.

本新闻稿包含“前瞻性声明”。前瞻性声明包括有关公司临床试验、候选产品和研究工作的声明，包括与FHD-286、FHD-909及其选择性CBP和EP 300降解剂计划有关的声明，以及其他以“可能”、“可能”、“可能”、“会”、“可能”、“预期”、“打算”、“计划”、“寻求”、“相信”、“估计”、“期望”、“继续”、“项目”等词语标识的声明，以及对未来时期的类似引用。

Forward-looking statements are based on our current expectations and assumptions regarding capital market conditions, our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict.

前瞻性陈述基于我们目前对资本市场状况、我们的业务、经济和其他未来状况的预期和假设。由于前瞻性陈述与未来有关，就其性质而言，它们受到难以预测的固有不确定性、风险和环境变化的影响。

As a result, actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions, including risks relating to our clinical trials and other factors set forth under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission.

因此，实际结果可能与前瞻性声明所预期的结果存在重大差异。可能导致实际结果与前瞻性声明中的结果产生重大差异的重要因素包括地区、国家或全球政治、经济、商业、竞争、市场和监管条件，包括与我们的临床试验相关的风险以及公司提交给证券交易委员会的截至2023年12月31日的年度报告表格10-K中“风险因素”标题下列出的其他因素。

Any forward-looking statement made in this press release speaks only as of the date on which it is made..

本新闻稿中的任何前瞻性声明仅在发布之日起生效。。

Contacts:

联系人：

Greg Dearborn, Foghorn Therapeutics Inc. (Investors)

Greg Dearborn，Foghorn Therapeutics Inc.（投资者）

gdearborn@foghorntx.com

Karin Hellsvik, Foghorn Therapeutics Inc. (Investors & Media)

卡林·赫尔斯维克（Karin Hellsvik），福格霍恩治疗公司（Investors&Media）

khellsvik@foghorntx.com

Adam Silverstein, ScientPR (Media)

Adam Silverstein，山达公关（媒体）